BidaskClub upgraded shares of Adamas Pharmaceuticals (NASDAQ:ADMS) from a strong sell rating to a sell rating in a research report sent to investors on Friday morning.

Other analysts have also issued research reports about the company. HC Wainwright set a $40.00 price target on Adamas Pharmaceuticals and gave the company a buy rating in a report on Monday, January 14th. Zacks Investment Research upgraded Adamas Pharmaceuticals from a sell rating to a hold rating in a report on Thursday, February 7th. Leerink Swann started coverage on Adamas Pharmaceuticals in a report on Monday, November 12th. They issued an outperform rating and a $20.00 price target for the company. Cowen set a $30.00 price target on Adamas Pharmaceuticals and gave the company a buy rating in a report on Thursday, November 1st. Finally, Mizuho lowered Adamas Pharmaceuticals from a buy rating to a neutral rating and lowered their price target for the company from $75.00 to $18.00 in a report on Monday, November 5th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. Adamas Pharmaceuticals presently has an average rating of Hold and a consensus target price of $31.25.

Shares of ADMS traded up $0.61 during mid-day trading on Friday, reaching $10.53. 632,093 shares of the company’s stock traded hands, compared to its average volume of 460,547. The stock has a market cap of $287.85 million, a price-to-earnings ratio of -2.65 and a beta of 1.41. Adamas Pharmaceuticals has a 12 month low of $7.42 and a 12 month high of $34.72. The company has a debt-to-equity ratio of 1.01, a quick ratio of 8.74 and a current ratio of 8.95.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. First Mercantile Trust Co. grew its position in Adamas Pharmaceuticals by 43.2% during the 4th quarter. First Mercantile Trust Co. now owns 5,765 shares of the specialty pharmaceutical company’s stock worth $49,000 after purchasing an additional 1,740 shares during the period. Advisor Group Inc. grew its position in Adamas Pharmaceuticals by 252.0% during the 4th quarter. Advisor Group Inc. now owns 6,300 shares of the specialty pharmaceutical company’s stock worth $54,000 after purchasing an additional 4,510 shares during the period. Pacer Advisors Inc. acquired a new stake in Adamas Pharmaceuticals during the 3rd quarter worth about $104,000. Barclays PLC grew its position in Adamas Pharmaceuticals by 87.6% during the 4th quarter. Barclays PLC now owns 17,387 shares of the specialty pharmaceutical company’s stock worth $148,000 after purchasing an additional 8,118 shares during the period. Finally, Assenagon Asset Management S.A. acquired a new stake in Adamas Pharmaceuticals during the 4th quarter worth about $161,000. 88.26% of the stock is currently owned by hedge funds and other institutional investors.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.

Recommended Story: What is the Bid-Ask Spread?

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.